SCHEMBL2265488

SCHEMBL2265488

Nc1cc(Cl)c(CC(N)C(=O)O)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 3/20 0.44
PKM P14618 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALOX15 P16050 2/20 0.44
HIF1A Q16665 2/20 0.44
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 2/20 0.44
RECQL P46063 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
RGS12 O14924 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
NFKB1 P19838 1/20 0.44
CASP1 P29466 1/20 0.44
BRCA1 P38398 1/20 0.44
THPO P40225 1/20 0.44
CASP7 P55210 1/20 0.44
GNAI1 P63096 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5327704 0.85 SLC7A5 (0.50) USP2PKMMEN1KMT2AALOX15
SCHEMBL5327701 0.85 SLC7A5 (0.50) USP2PKMMEN1KMT2AALOX15
SCHEMBL7818683 0.80 GRB2 (0.45) USP2PKMMEN1KMT2AALOX15
SCHEMBL7818681 0.80 GRB2 (0.45) USP2PKMMEN1KMT2AALOX15
SCHEMBL29398675 0.79 SLC7A5 (0.55) PKMMEN1KMT2AALOX15HSD17B10
SCHEMBL29397997 0.79 SLC7A5 (0.55) PKMMEN1KMT2AALOX15HSD17B10
SCHEMBL28839577 0.79 SLC7A5 (0.55) PKMMEN1KMT2AALOX15HSD17B10
SCHEMBL22775719 0.78 SLC7A5 (0.49) PKMMEN1KMT2AHSD17B10CYP3A4
Hydrochloric Acid SCHEMBL27984647 0.78 SLC7A5 (0.53) PKMMEN1KMT2AALOX15HSD17B10
SCHEMBL17340412 0.78 GRIA1 (0.49) USP2PKMMEN1KMT2AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 USP2 482/4885PKM 2733/4885MEN1 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.